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Abstract
Background: We investigated the role of human HLA class I molecules in persistent central nervous system (CNS)
injury versus repair following virus infection of the CNS.
Methods: Human class I A11+ and B27+ transgenic human beta-2 microglobulin positive (Hβ2m+) mice of the H-2b
background were generated on a combined class I-deficient (mouse beta-2 microglobulin deficient, β2m0) and
class II-deficient (mouse Aβ0) phenotype. Intracranial infection with Theiler’s murine encephalomyelitis virus (TMEV)
in susceptible SJL mice results in acute encephalitis with prominent injury in the hippocampus, striatum, and cortex.
Results: Following infection with TMEV, a picornavirus, the Aβ0.β2m0 mice lacking active immune responses died
within 18 to 21 days post-infection. These mice showed severe encephalomyelitis due to rapid replication of the
viral genome. In contrast, transgenic Hβ2m mice with insertion of a single human class I MHC gene in the absence
of human or mouse class II survived the acute infection. Both A11+ and B27+ mice significantly controlled virus RNA
expression by 45 days and did not develop late-onset spinal cord demyelination. By 45 days post-infection (DPI),
B27+ transgenic mice showed almost complete repair of the virus-induced brain injury, but A11+ mice conversely
showed persistent severe hippocampal and cortical injury.
Conclusions: The findings support the hypothesis that the expression of a single human class I MHC molecule,
independent of persistent virus infection, influences the extent of sub frequent chronic neuronal injury or repair in
the absence of a class II MHC immune response.
Keywords: Theiler’s murine encephalomyelitis virus, Virus persistence, Picornavirus, Human leukocyte antigen, Major
histocompatibility complex
Background
The factors that control persistent injury versus repair
following damage to the central nervous system (CNS)
remain poorly understood. Class I major histocompati-
bility complex (MHC) molecules are cell surface glyco-
proteins that are critical for the development of cellular
immunity and are expressed in almost every nucleated
cell of the body. Upon pathogen invasion, foreign pep-
tide fragments are presented to CD8+ T cells via the
MHC class I proteins. CD8+ T cells in response secrete
cytokines that target and kill cells presenting specific
MHC-antigen complexes. This mechanism arrests the
systemic pathogen spread primarily via a perforin-
mediated pathway [1]. The CNS was previously consid-
ered immune-privileged as neurons did not appear to
express MHC class I molecules [2]. However, Neumann
et al. demonstrated induction of class I MHC genes in
cultured rat hippocampal neurons. These results dem-
onstrated cell surface expression of MHC class I mole-
cules in electrically silent neurons stimulated with
interferon gamma [3]. More recent studies reported low
level MHC class I expression in CNS neurons under
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physiological conditions. The importance of MHC class
I molecules in neuronal development and CNS plasticity
was further strengthened by the fact that neural activity
regulates class I MHC gene expression in the developing
and mature CNS [4]. Class I MHC molecules are also
necessary for normal regressive events in the developing
and adult CNS including activity-dependent synaptic
weakening and structural refinement [5]. MHC class I
molecules are present both pre- and post-synaptically in
the visual cortex during postnatal development and in
adulthood [6]; MHC class I molecules function on both
sides of the synapse before, during, and after the estab-
lishment of connections in the mammalian visual cortex
[7]. The expression of MHC class I is proportional to in-
creased neural activity in the developing visual system
and in the adult hippocampus after seizures [4]. Inter-
estingly, increased expression of MHC class I is a known
trigger for neurogenesis. Accordingly, both toll-like re-
ceptors expressed by adult neural stem cells and T cells
also modulate neurogenesis [8–10], thus providing pre-
cedence for the hypothesis that MHC class I is involved
in the development and perhaps regeneration of the
CNS neurons. Finally, recent studies described the presence
of functional lymphatic vessels lining the dural sinuses
[11, 12]. These structures express all of the molecular
hallmarks of lymphatic endothelial cells, are able to
carry both fluid and immune cells from the cerebrospinal
fluid, and are connected to the deep cervical lymph nodes.
This suggests the brain is like every other tissue, con-
nected to the peripheral immune system through menin-
geal lymphatic vessels and questions the classification of
CNS as an immune-privileged organ devoid of lymphatic
vasculature [2].
A large body of investigative work on CNS injury has
been documented in rodent models. In contrast, studies
investigating the role of the human immune responses
contributing to this process are very limited. In an attempt
to address this problem, we made a series of human
leukocyte antigen (HLA) transgenic mice. The mice ori-
ginally lacked both class I (beta-2 microglobulin deficient,
β2m0) and class II (Aβ0). These mice develop normally
despite the absence of endogenous CD4+ T cell-restricted
class II immune responses or CD8+ T cell-restricted class I
immune responses. HLA-A11 and B27 molecules were as-
sociated with viral infections [13–16] or associated with
ankylosing spondylitis, reactive arthritis, uveitis, and other
associated inflammatory diseases [17–19], respectively.
To study the role of the human class-I immune response
in CNS injury and repair, we crossed the Aβ0.β2m0 mice
to express human beta-2 microglobulin (Hβ2m), which
were then paired with either the A11 or B27 human class
I gene to generate a functional molecule. Therefore, any
immune response observed in Aβ0.β2m0.Hβ2m+.A11+
and Aβ0.β2m0.Hβ2m+.B27+ mice would be a direct
consequence of the human class I gene because the
class II immune response was deleted.
Infection with Theiler’s murine encephalomyelitis virus
(TMEV) in different mouse strains results in two distinct
phenotypes. In animals (C57BL/6 or C57BL/10 mice)
that are resistant to demyelination and persistent infec-
tion, the virus during the first 10 to 12 days of infection
replicates primarily in neurons of the hippocampus, stri-
atum, cortex of the brain, and anterior horn cells of the
spinal cord. In immunocompetent mice the virus is rapidly
cleared from these cells irrespective of MHC haplotype in
association with an intense inflammatory response [20]
such that virus persistence and subsequent demyelination
in the spinal cord does not occur. Oligodendrocytes and
macrophages are also infected early [21]. In mice of re-
sistant MHC haplotypes H-2b,d,k, no virus persistence
develops and therefore no demyelination in the spinal
cord ensues [22]. In animals of susceptible MHC haplo-
type H-2s,v,r,u,f,q, the virus infects neurons during the
early phase similar to “resistant” mice; however, virus
persists in glial cells [23] and macrophages [24–26],
particularly in the spinal cord white matter and brain
stem during the chronic stage (21–45 days post-infection).
This results in primary demyelination, inflammation,
axonal loss, and neurologic deficits that mimic human
multiple sclerosis. In susceptible mice, demyelination with
chronic deficits persists throughout the life of the animal.
By studying Theiler’s infection in resistant BALB/c
mice, other investigators showed CD8+ T cells to play a
protective role, possibly as suppressor cells [27, 28]. In
animals susceptible to TMEV infection, activated cytotoxic
T cells are generated in the brain [29] without apparent
viral or myelin specificity [30]. During the chronic phase
of demyelination, some susceptible strains of mice demon-
strate “epitope spreading” to myelin antigens [31]. Demye-
lination in association with an intense inflammatory
response begins in the spinal cord around day 21 following
infection and is well established by day 45. Demyelination
in these mice continues to worsen until approximately
90–100 days post-infection (dpi), but then reaches a plat-
eau [32]. However, the animals continue to worsen neuro-
logically for another subsequent 100 days after infection as
a result of loss of large-diameter axons from the spinal
cord, progressive spinal cord atrophy, and absence or min-
imal remyelination [32]. Virus persistence is detected both
as RNA, antigen, and infectious particles throughout the
course of the disease in a susceptible mouse. An important
aspect of this model is severe injury of the hippocampus,
striatum, and cortex in the early phase of infection (7 dpi),
in both susceptible and resistant strain of mice, which is
subsequently repaired by 45 dpi. In “resistant” strains of
mice, viral RNA is cleared, whereas in “susceptible” strains
of mice, viral RNA persists throughout the life of the ani-
mal. Therefore, control of persistent virus infection is not
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the factor that controls repair of early injury in the hippo-
campus, striatum, and cortex following TMEV infection.
In the current study, we investigated whether the ex-
pression of a single human class I MHC molecule will
influence neuronal injury versus repair following acute
viral injury of the hippocampus, striatum, and cortex.
We studied the role of human class I response in the ab-
sence of a competent class II MHC immune response
and also independent of persistent TMEV infection.
Methods
Mice
All transgenic and knockout mice were generated in the
Mayo Clinic College of Medicine transgenic core facility
under the direction of Dr. Chella David. All breedings
were carried out in the barrier facility of the Immunoge-
netics mouse colony of the Mayo Clinic, Rochester, MN,
USA. Aβ0 mice: Founder mice lacking functional mouse
MHC class II molecules (Aβ0) were kindly provided by
Drs. Diane Mathis and Christophe Benoist (INSERM,
Strasbourg France; Cosgrove et al. [33]). β2m0 mice:
Founder mice lacking functional mouse MHC class I
molecules (β2m0) were a kind gift from Dr. Beverly
Koller, University of North Carolina, Chapel Hill, NC
[34]. Aβ0.β2m0 mice: The Aβ0 and β2m0 mice were
mated in order to obtain Aβ0.β2m0 mice that were then
bred in the Immunogenetics facility. Aβ0.β2m0.Hβ2m+
mice: The Aβ0.β2m0 mice were crossed to human β2m
(Hβ2m+) transgenic mice [35] (gift of Dr. Hidde Plough,
Massachusetts Institute of Technology, Boston, MA) to
obtain Aβ0.β2m0.Hβ2m+ mice. Aβ0.β2m0.Hβ2m+.A11+
mice: transgenic HLA-A11/Kb (A11+) mice [36] were a
kind gift from Dr. Jeff Alexander. The A11+ mice were
mated to Aβ0.β2m0.Hβ2m+ mice in order to obtain
Aβ0.β2m0.Hβ2m+.A11+ mice. All the A11 transgenic mice
used in these studies were in the fifth to eighth backcross
generation. Aβ0.β2m0.Hβ2m+.B27+ mice: β2m deficient
mice [34] were mated with human β2m (Hβ2m+) trans-
genic mice [35]. Hβ2m+ littermates were intercrossed to
generate a mouse having homozygous mutation of en-
dogenous β2m gene replaced with human β2m gene
(β2m0.Hβ2m+). The β2m0.Hβ2m+ mice were mated with
previously described Aβ0.β2m0.B27+ animals [37] to ob-
tain Aβ0.β2m0.Hβ2m+.B27+ mice. Aβ0.β2m0.B27+ animals
lack normal expression of H2-Kb and H2-Db and were
used as negative controls during the flow cytofluorometry
analysis. All the B27 transgenic mice used in these studies
were in the fifth to eighth backcross generation. All ani-
mals described here bred normally and showed no abnor-
mal signs of brain or systemic disorder. Originally, we had
two founder mice for each transgenic. However, one did
not breed and died, and thus, all experiments are based on
one transgenic mouse for each strain. C57BL/6 (negative
control that clears infection) and SJL/J (positive control
that develops persistent infection and demyelination) mice
were obtained from the Jackson Laboratories (Bar Harbor,
Maine). Mice were followed daily until they were mori-
bund. Mice that survived the acute infection were sacri-
ficed at 45 dpi (endpoint of the study) for pathology and
virus RNA expression.
Screening of mice
In the absence of endogenous mouse β2m, MHC class I
molecules have low expression on the cell surface.
Therefore, the presence of MHC class I transgenes in
β2m0 mice was analyzed by polymerase chain reaction
(PCR). DNA was extracted from the peripheral blood ac-
cording to manufacturer’s instructions using the Gentra
Puregene Blood Kit (Qiagen, Germantown, MD). Four
milliliters of DNA was added to 0.2 μM dNTPs, 1.0 μM
each 3′ and 5′ primers in the PCR buffer in a total vol-
ume of 25 μl. Taq polymerase (0.625 U) was added to
this mixture and amplified in 30 cycles under the follow-
ing conditions: 3 min at 94 °C (94 °C for 1 min, anneal-
ing temp 62 °C for 1 min and 72 °C for 1 min) × 30 and
7 min at 72 °C. PCR products were analyzed by electro-
phoresis, and their molecular weight was compared with
a standard molecular weight marker. Presence of MHC
class I transgenes was identified by PCR using the fol-
lowing pair of oligonucleotide sequences: HLA-A11: 5′
(GGG CTC TCA CTC CAT GAG GTA TTC) and 3′
(TGT GAG TGG GCC TTC ACT TTC C); HLA-B27:
5′ (CCA CTC CAT GAG GTA TTT CCA) and 3′ (CTG
TGC CTT GGC CTT GCA GA).
Flow cytofluorometry
Human β2m, Kb and Db identification was carried out
by FACS using L-368, B8-24-3 (American Type Culture
Collection, Rockville, MD) and 172-93.1 (kind gift of
Dr. Günter Hammerling, DKFZ, Heidelberg) antibodies,
respectively. Briefly, mononuclear cells from peripheral
blood were incubated with antibodies for 30 min at 4 °C.
After washing with FACS® buffer (PBS containing 1% bo-
vine serum albumin and 0.1% sodium azide) (Becton Dick-
inson and Co., San Jose, CA), cells were incubated with
fluorescence-labeled secondary antibody (IgG goat anti-
mouse Fab’2; Accurate Chemical and Scientific Corp.,
Westbury, NY). Expression of cell surface molecules was
analyzed on 10,000 gated lymphocytes on forward and
side scatter by flow cytometry.
Virus infection and harvesting of the CNS for morphology
Transgenic mice were anesthetized and intracerebrally
injected at 6 to 8 weeks of age with 2 × 105 p.f.u.
(plaque-forming units) of the Daniel’s strain of TMEV in
a 10 μl volume. This resulted in >98% incidence of infec-
tion with rare fatalities [38]. At various times after infec-
tion, mice were perfused via intracardiac puncture with
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50 ml of Trump’s fixative. Spinal cords and brains were re-
moved and post-fixed for 24 to 48 h in Trump’s fixative in
preparation for morphologic analysis.
Spinal cord morphometry
Spinal cords were removed from spinal columns and cut
into 1-mm coronal blocks. Every third block was osmicated
and embedded in glycol methacrylate. Two-micron sections
were prepared and stained with a modified erichrome/cre-
syl violet stain [39]. Morphological analysis was performed
on 12 to 15 sections per mouse as previously described
[40]. Briefly, each quadrant from every coronal section from
each mouse was graded for the presence or absence of
gray-matter disease, meningeal inflammation, and demye-
lination. The score was expressed as the percentage of
spinal cord quadrants examined with the pathologic abnor-
mality. A maximum score of 100 indicated a particularly
pathologic abnormality in every quadrant of all spinal cord
sections of a given mouse. All grading was performed
without knowledge of the experimental group on coded
sections. Additional spinal cord blocks were embedded
in paraffin for immunocytochemistry.
Brain pathology
Brain pathology was assessed at various time points
post-infection using our previously described technique
[41]. Following perfusion with Trump’s fixative, two cor-
onal cuts were made in the intact brain at the time of re-
moval from the skull (one section through the optic
chiasm and a second section through the infundibulum).
As a guide, we used the Atlas of the Mouse Brain and
Spinal Cord corresponding to sections 220 and 350, page
6 [42]. This resulted in three blocks that we embedded
in paraffin. This allowed for systematic analysis of the
pathology of the cortex, corpus callosum, hippocampus,
brainstem, striatum, and cerebellum. The resulting slides
were then stained with hematoxylin and eosin. Pathologic
scores were assigned without knowledge of experimental
group to the following areas of the brain: cortex, corpus
callosum, hippocampus, brainstem, striatum, and cerebel-
lum. Each area of the brain was graded on a 5-point scale
(0 = no pathology; 1 = no tissue destruction but only min-
imal inflammation; 2 = early tissue destruction [loss of
architecture] and moderate inflammation; 3 = definite tis-
sue destruction [demyelination, parenchymal damage, cell
death, neurophagia, neuronal vacuolation]; 4 = necrosis
[complete loss of all tissue elements with associated
cellular debris]). Meningeal inflammation was assessed
and graded as follows: 0 = no inflammation; 1 = one cell
layer of inflammation; 2 = two cell layers of inflammation;
3 = three cell layers of inflammation; 4 = four or more cell
layers of inflammation. We scored the brain region with
the maximal extent of tissue damage.
Immune-staining for human transgene proteins
Whole brains were removed from animals at 45 dpi,
snap frozen, and sectioned at 10 μm in a cryostat. Acet-
one fixed sections were air dried and then blocked with
4% BSA:1X PBS and then incubated with anti-HLA B27
[EP-4] or anti-HLA A11 [4i93]; (Abcam Inc, Cambridge,
MA). Immunoreactivity was detected using mouse on
mouse HRP-Polymer (Biocare Medical, LLC, Concord, CA)
and 3,3′ diaminobenzidine (Sigma #D5637).
Immune-staining for virus protein
We performed immunocytochemistry on paraffin-
embedded sections as previously described. Slides
were de-paraffinized in xylene and rehydrated
through an ethanol series (absolute, 95, 70, and
50%). Virus antigen staining was carried out using
rabbit polyclonal antisera to TMEV-DA [43], which
reacts strongly with the capsid proteins of TMEV.
Following incubation with a secondary biotinylated
antibody (Vector Laboratories, Burlingame, CA), im-
munoreactivity was detected using the avidin-biotin
immunoperoxidase technique (Vector Laboratories).
The reaction was developed using Hanker-Yates reagent
with hydrogen peroxide as the substrate (Polysciences,
Warrington, PA). Slides were lightly counterstained
with Mayer’s hematoxylin. The data were expressed as
the percentage of spinal cord quadrants showing virus
antigen-positive cells in either the gray matter or white
matter in the spinal cord.
RNA isolation
The brain and spinal cords were removed from animals
infected with TMEV. Total RNA was extracted from
brain and spinal cord [44]. Briefly, the tissues were fro-
zen and stored in liquid nitrogen. Tissues samples were
homogenized in the RNA STAT-60 (1 ml/100 mg tissue)
(TEL-TEST, INC., Friendswood, TX) with a homogenizer,
and total RNA was isolated according to the manufac-
turer’s recommendations. The RNA concentrations were
determined by spectrophotometer. The RNA samples
were equilibrated to a concentration of 0.25 μg/μl and
stored at −80 °C.
RT-PCR and real-time analysis for virus RNA
The VP2 fragment of TMEV, a viral capsid region of DA
virus, was amplified by RT-PCR using gene-specific
primers [44]. The primer pair sequences for VP2 of DA
virus were as follows: forward (5′-TGGTCGACTCTGT
GGTTACG-3′) and reverse (5′-GCCGGTCTTGCAAAG
ATAGT-3′). Gluceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as a control for inter-sample variability.
The sequences used for assaying the presence of GAPDH
were as follows: forward (5′-ACCACCATGGAGAAGGC-
3′) and reverse (5′-GGCATGGACTGTGGTCATGA-3′).
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Sizes of PCR products amplified with primers were 238
base pairs for VP2 and 236 base pairs for GAPDH.
Gene-copy standards were generated with each set of
samples. Standards were generated by serial tenfold dilu-
tions of plasmid cDNA. Standards were amplified in par-
allel with unknown samples by real-time quantitative
RT-PCR using the LightCycler (Roche, Indianapolis, IN).
We used LightCycler 3 software analysis to generate
standard curves. Negative controls (omitting input cDNA)
were also used in each PCR run to confirm the specificity
of the PCR products. PCR product curves were linear
across serial tenfold dilutions, and the melting curve ana-
lysis indicated synthesis of a single homogenous product
of the expected melting temperature. The reactions were
done in 20-μl capillaries 7.0 mM Mg2+, 10 pM concen-
trations of each forward and reverse primer, 4.0 μl of
LightCycler-RT-PCR Reaction Mix SYBR Green I (Light-
Cycler-RNA Amplification Kit SYBR Green I; Roche), 2 μl
of resolution solution, 0.4 μl of LightCycler-RT-PCR En-
zyme Mix, sterile H2O, and 0.5 μg total RNA. Reaction
conditions for RT-PCR for VP2 and GAPDH were as fol-
lows: reverse transcription at 55 °C for 10 min, followed
by denaturation at 95 °C for 2 min, followed by 40 cycles
of amplification. Amplification conditions were as follows:
denaturing at 95 °C at 20 °C/s without plateau phase, an-
nealing at 57 °C for 7 s, and extension 72 °C for 15 s. The
accumulation of products was monitored by SYBR Green
fluorescence at the completion of each cycle. There was a
direct relationship between the cycle number at which ac-
cumulation of PCR products became exponential and the
log concentration of RNA molecules initially present in
the RT-PCR reaction. The reaction conditions for melting
curve analysis were as follows: denaturation to 95 °C at
20 °C/s without plateau phase, annealing at 60 °C for 5 s,
and denaturation to 95 °C at 0.1 °C/s, with continuous
monitoring of SYBR Green fluorescence. RNA samples
(n = 76) from DA virus-infected mice were analyzed for
GAPDH mRNA levels to determine the levels of mRNA
per sample and the technical reproducibility. The GAPDH
mRNA level per sample was log10 7.19 ± 0.02 (mean ± the
SEM). Therefore, the marked variations in viral RNA
levels in individual specimens could not be attributed to
differences in amplifiable material. The amount of viral
RNA was expressed as log10 virus copy number/0.5 μg
RNA total. We used viral RNA as the primary assay for
virus infection since plaque assays are difficult and many
times unreliable with Theiler’s virus [45]. Previous work
from our lab has shown an excellent correlation between
virus RNA and plaque assay [46].
Virus-specific antibody isotype ELISA
Whole blood was collected from mice at time of sacrifice,
and sera was isolated and stored at –80 °C until further
use. Total serum IgG against TMEV was assessed by
enzyme-linked immunosorbent assay (ELISA) as described
[47]. Purified virus was adsorbed on 96-well plates (Immu-
lon II; Dynatech Laboratories Inc., Chantilly, VA) and then
blocked with 1.0% bovine serum albumin (BSA; Sigma
Chemical Co. St. Louis, MO) in PBS. Serial dilutions of
sera were made in 0.2% BSA/PBS and added in triplicate.
Biotinylated anti-mouse IgG secondary antibodies were
used for detection (Jackson Immunoresearch Labs,
Westbury, NY). Signals were amplified with streptavidin-
labeled alkaline-phosphatase (Jackson Immunoresearch
Labs) and detected using p-nitrophenyl phosphate as the
substrate. Absorbances were read at 405 nm and plotted
as a function of serum dilution factors.
Statistics
Data were analyzed using either the Student’s t test for
normally distributed data or the Mann-Whitney rank
sum test for data that were not normally distributed.
ANOVA was used for comparisons of more than one
group. The Siegel-Tukey test was used for all pair-wise
multiple comparison procedures. Proportional data were
evaluated using the z-test. The level for significance was
set as P < 0.05 for all tests.
Results
Derivation of transgenic mice and expression of MHC
class I molecules
Aβ0, β2m0, and Aβ0.β2m0 mice were obtained as de-
scribed in the “Methods” section. Aβ0.β2m0 mice have
no functional class II (CD4+ T cells) or class I (CD8+ T
cells) immune responses. To simulate expression of hu-
man HLA molecules on cell surface, we replaced mouse
endogenous β2m with human β2m transgene and gener-
ated Aβ0.β2m0.Hβ2m+. These mice were then subsequently
crossed with mice expressing the HLA-A11 transgene to
obtain Aβ0.β2m0.Hβ2m+.A11+ mice. β2m0.Hβ2m+ mice
were mated with HLA-B27 transgene positive mice
(β2m0.B27+) to generate β2m0.Hβ2m+.B27+ mice. These
were then crossed with Aβ0 mice to obtain
Aβ0.β2m0.Hβ2m+.B27+ mice. The Aβ0.β2m0.Hβ2m+.A11+
and Aβ0.β2m0.Hβ2m+.B27+ mice did not show expression
of Aβ0 (Fig. 1a). We also noted that expression of human
β2m (Fig. 1b) in the context of transgenes HLA-A11 and
HLA-B27 restored normal expression of endogenous
mouse class I (H2-Kb and H2-Db) molecules. The level of
expression of H2-Kb and H2-Db was similar between
Aβ0.β2m0.Hβ2m+.A11+ and Aβ0.β2m0.Hβ2m+.B27+ mice
(Fig. 1c, d). The presence of MHC class I transgenes A11
and B27 was identified by PCR using oligonucleotide se-
quences described in the “Methods” section. Immuno-
staining of brain sections confirmed the expression of A11
(Additional file 1: Figure S1A, B) or B27 (Additional file 1:
Figure S1C, D). However, the level of immunostaining in
brain sections was very low as seen by the figures because
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of the difficulty of finding antibodies that worked well for
immunocytochemistry and the low level of MHC normally
observed in CNS.
Transgenic expression of human class I A11+ or B27+ gene
prevents death of TMEV-infected Aβ0.β2m0.Hβ2m+ mice
Previous experiments performed with Aβ0.β2m0 mice
demonstrated that these mice die of overwhelming
virus-induced encephalomyelitis within 16 to 18 dpi with
TMEV [48]. We infected Aβ0.β2m0 mice (N = 25) with
TMEV, and mice were either moribund or dead by 18
dpi. As controls, we infected β2m0 mice (N = 27), Aβ0
mice (N = 38), and C57BL/6 mice (N = 26) that showed
only mild early neurologic deficits, and all survived past
18 dpi.
We then asked whether the expression of a single class
I human HLA transgene in lieu of mouse class I would
protect mice from death. We hypothesized that substitu-
tion of the mouse class I gene with the human class I
gene would generate a line of mice that are similar to
Aβ0 mice. We infected Aβ0.β2m0.Hβ2m+.A11+ (N = 72),
Aβ0.β2m0.Hβ2m+.B27+ (N = 29), and Aβ0.β2m0.Hβ2m+
(N = 11) mice with TMEV. As expected, all mice survived
past the 18-day time point with minimal early neurologic
deficits. We chose to sacrifice these human class I trans-
genic MHC mice at 7 dpi (time of maximal viral replica-
tion and early CNS pathology) or 45 dpi for pathologic
and virology analyses. We decided to examine surviving
mice at 45 dpi, because this time point has been used pre-
viously in past studies [49] to determine viral persistence
and spinal cord demyelination, when mice are entering
the chronic phase of infection.
Expression of human class I MHC transgenes prevents
severe early neuronal gray matter disease observed in
TMEV-infected Aβ0.β2m0 mice
Having observed that expression of human class I MHC
transgene protects Aβ0.β2m0 mice from death following
a lethal dose of virus in the mouse CNS, we subse-
quently examined spinal cord pathology (Table 1). Spinal
cord sections were studied at 18 to 21 dpi. We quanti-
fied the percentage of spinal cord quadrants with neur-
onal injury in the gray matter and demyelination and
inflammation in the white matter. Gray matter disease
was characterized by neuronal loss, intense inflammation
around anterior horn cells, and vacuolar degeneration
of neurons. The number of spinal cord quadrants with
neuronal injury particularly in the gray matter were
Fig. 1 Flow cytometric analysis in Aβ0.β2m0.Hβ2m+.A11+ and Aβ0.β2m0.Hβ2m+.B27+ mice. Cell surface expression was examined by antibodies to
Aβ (Aβ-163), Hβ2m (L-368), H2-Kb (B8-24-3) and H2-Db (172-93.1). Controls were B10 (Aβ+.Hβ2m−), Aβ0, Kb0.Db0.β2m0.Hβ2m+, and C57BL/6 (Kb+.Db+)
mice. In each panel, the gray histogram represents negative control, the green histogram represents a positive control, and the red and blue histograms
represent Aβ0.β2m0.Hβ2m+.A11+ and Aβ0.β2m0.Hβ2m+.B27+ mice, respectively. Non-expression of Aβ (a) and expression of Hβ2m (b), H2-Kb (c), and
H2-Db (d) in transgenic human class I mice is shown
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increased in Aβ0.β2m0 mice (13.0 ± 3.1, N = 21) compared
to the gray matter of immunocompetent C57BL/6 mice
(0.0 ± 0.0, N = 11). The decrease in the gray matter disease
in C57BL/6 mice compared to Aβ0.β2m0 mice was statisti-
cally significant (P = 0.005, rank sum test). Similar (low)
levels of gray matter spinal cord pathology was ob-
served in β2m0 mice (1.3 ± 0.6, N = 11) and in Aβ0 mice
(0.0 ± 0.0, N = 13). Meningeal inflammation was observed
in Aβ0.β2m0 (4.4 ± 1.8, N = 21) and β2m0 (3.4 ± 0.7,
N = 11) mice, whereas no inflammation was observed in
C57BL/6 (0.0 ± 0.0, N = 11) mice or Aβ0 mice (0.0 ± 0.0,
N = 13). The difference in meningeal inflammation was
statistically significant (P < 0.001, ANOVA on ranks),
when comparing Aβ0.β2m0, Aβ0, β2m0, and C57BL/6 mice.
Next, we studied mice with human class I transgenes
infected with TMEV for 21 days. The extent of gray-matter
pathology in the spinal cord at 21 days was 0.1 ± 0.1
for Aβ0.β2m0.Hβ2m+.A11+ (N = 7) mice and 0.0 ± 0.0
for Aβ0.β2m0.Hβ2m+.B27+ (N = 5). Therefore, trans-
genic insertion of a human class I gene almost com-
pletely eliminated neuronal injury in the spinal cord
during the early phase of disease. Similarly, the extent
of inflammation (Aβ0.β2m0.Hβ2m+.A11+ [0.3 ± 0.3] or
Aβ0.β2m0.Hβ2m+.B27+ [0.0 ± 0.0]) or demyelination
(Aβ0.β2m0.Hβ2m+.A11+ [0.0 ± 0.0] and Aβ0.β2m0.Hβ2m+.B27+
[0.0 ± 0.0]) in the class I transgenic mice was low or
completely absent. Therefore, the survival of mice as a
result of the insertion of the human class I transgenes
was associated with minimal pathology in the spinal
cord gray matter and minimal demyelination in the white
matter during the early disease phase.
Expression of A11+ or B27+ human class I transgene
protects mice from spinal cord demyelination
Having established that expression of either A11+ or B27+
transgenes protects Aβ0.β2m0 mice from acute spinal cord
gray-matter disease, we asked whether the expression of
these human genes would influence demyelination at 45
dpi (Fig. 2a). Aβ0.β2m0 mice were not available for these
analyses, since none survived to this time point. As de-
scribed previously, both β2m0 mice [40] and Aβ0 mice
[47] showed demyelination in the spinal cord white
matter. The percent (±SEM) of spinal cord quadrants
with demyelination was 10.7 ± 3.1 for β2m0 mice (N = 7)
and 5.0 ± 2.6 for Aβ0 mice (N = 19). Immunocompetent
C57BL/6 mice (N = 18) of resistant haplotype showed no
demyelination (0.0 ± 0.0). The difference in demyelination
between β2m0 mice and C57BL/6 mice was statistically
significant (P < 0.001, Mann-Whitney rank sum test).
Similarly, the increase in demyelination in β2m0 mice
compared to Aβ0 mice was statistically significant (P =
0.011, Mann-Whitney rank sum test). As a positive control,
we used highly susceptible SJL/J mice infected for 45 days
that showed significant meningeal inflammation (23.6 ± 3.7,
N = 17) and demyelination (24.9 ± 4.1, N = 17) in the spinal
cord. At 45 dpi (Fig. 2a), only a few spinal cord quadrants
showed demyelination in Aβ0.β2m0.Hβ2m+.A11+ (2.3 ± 0.9,
N = 16) or Aβ0.β2m0.Hβ2m+.B27+ (1.8 ± 0.8, N = 11) mice,
as compared to susceptible SJL/J mice (24.9 ± 4.1, N = 17).
There was no statistical difference in the number of spinal
cord quadrants with demyelination when comparing
Aβ0.β2m0.Hβ2m+.A11+, Aβ0.β2m0.Hβ2m+.B27+ or Aβ0
mice (ANOVA or ranks, Fig. 2b). In addition, there was
no significant difference in the number of spinal quadrants
with demyelination in Aβ0.β2m0.Hβ2m+.A11+ mice as
compared to Aβ0.β2m0.Hβ2m+.B27+ mice at 45 days after
infection (P = 0.767, rank sum test, Fig. 2b). We consid-
ered mice with less than 5% of the quadrants positive for
demyelination as resistant for spinal cord demyelination
and virus persistence, in contrast to susceptible strains
which usually show greater than 20% of the quadrants
positive for demyelination.
Expression of A11 results in the persistence of brain
injury, whereas expression of B27 results in brain repair
We investigated whether expression of A11 or B27 pro-
tected specific populations of brain cells from injury.
Using a 5-point scale (materials and methods), we first
assessed brain pathology at 7 dpi (Fig. 3a–g) to compare
the degree and extent of brain injury between the strains.
Scatter-point analyses of the brain pathology from
Aβ0.β2m0.Hβ2m+.A11+ and Aβ0.β2m0.Hβ2+.B27+ strains
showed similar pathology in the cortex, hippocampus,
striatum, and corpus callosum with minimal disease in
the cerebellum. Meningeal inflammation was similar in
both strains. Aβ0.β2m0.Hβ2m+.B27+ strain had a higher
predisposition to brain pathology in the corpus callo-
sum, striatum, and brain stem. For quantitative and
statistical comparisons, we compiled all pathology brain
scores into data sets segregated by strain and days after
infection. There was no statistical difference (P = 0.194,
rank sum test) in the pathologic scores at 7 days for
Aβ0.β2m0.Hβ2m+.A11+ mice (1.020 ± 0.186, N = 49) com-
pared to Aβ0.β2m0.Hβ2m+.B27+ mice (1.492 ± 0.205,
N = 63). Following the survival of Aβ0.β2m0.Hβ2m+.A11+
Table 1 Spinal cord pathology of TMEV-infected mice (45 dpi)
Strain Number Gray matter disease Meningeal
inflammation
Aβ0 19 0.5 ± 0.3 1.3 ± 0.7
β2m0 7 0.5 ± 0.3 9.7 ± 4.0
Aβ0.β2m0. Hβ2m+.A11+ 16 0.1 ± 0.1 0.9 ± 0.4
Aβ0.β2m0. Hβ2m+.B27+ 11 0.0 ± 0.0 0.4 ± 0.4
C57BL/6 18 0.0 ± 0.0 0.0 ± 0.0
SJL/J 17 0.4 ± 0.3 23.6 ± 3.7
Data expressed as the percent of spinal cord quadrants showing the
pathologic abnormality (mean ± SEM)
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and Aβ0.β2m0.Hβ2m+.B27+ mice past the 18-to-21 dpi as
compared to immune-deficient Aβ0.β2m0 mice, we asked
whether this phenomenon reflected the extent of brain
pathology. At 18 to 21 dpi, the brain pathologic scores
in Aβ0.β2m0 mice (1.714 ± 0.181, N = 56) were signifi-
cantly greater than in Aβ0.β2m0.Hβ2m+.A11+ mice
(0.796 ± 0.193, N = 49, P < 0.001, rank sum test) or for
Aβ0.β2m0.Hβ2m+.B27+ (0.943 ± 0.232, N = 35, P = 0.004,
rank sum test). Therefore, we concluded that the ex-
pression of a human class I gene protected Aβ0.β2m0
mice from lethal encephalitis.
We then addressed whether a particular human class I
MHC allele would influence persistent brain injury ver-
sus repair in the CNS following the early injury in both
strains in the hippocampus, striatum, and cortex. We
analyzed the distribution of brain disease at 45 dpi. The
difference in the pathological scores of the hippocampus
and the cortex was substantial between these strains.
There was similar severe loss of pyramidal cell neurons
in the hippocampus of both strains at 7 days after infec-
tion (Fig. 4a, b). Many areas showed frank necrosis with
complete loss of neuronal architecture (brain pathology
scores of 4, Fig. 3j, k, m). At 45 dpi in Aβ0.β2m0.Hβ2m+.B27+
mice, there was essentially complete repair of the
pyramidal cell layer of the hippocampus (Fig. 4d). In
contrast, the loss of pyramidal cells persisted in
Aβ0.β2m0.Hβ2m+.A11+ mice (Fig. 4c). Similar find-
ings were observed in the cerebral cortex, where
Aβ0.β2m0.Hβ2m+.B27+ mice showed normal cortical
neurons at 45 dpi, whereas Aβ0.β2m0.Hβ2m+.A11+ mice
showed cortical shrinkage as a manifestation of neuronal
loss. There was more brain pathology (Fig. 3h–n) at 45 dpi
(P = 0.027, rank sum test) in Aβ0.β2m0.Hβ2m+.A11+ mice
(0.964 ± 0.137, N = 112) than in Aβ0.β2m0.Hβ2m+.B27+
mice (0.403 ± 0.198, N = 77). These findings support the
hypothesis that the presence of the B27 allele results in a
class I-restricted immune response favoring repair. In
contrast, the presence of the A11 allele results in a
class I-restricted immune response favoring persistent
injury. To show the quantitative effect on the human
class I MHC genes in injury and repair present in the
hippocampus and striatum, we compared the combined
pathologic scores in these areas between Aβ0.β2m0.Hβ2m
+.A11+ and Aβ0.β2m0.Hβ2m+.B27+ mice. We found a
Fig. 2 a Chronic demyelination scores in spinal cords of different transgenic mice compared to wild-type mice. Morphological analysis of spinal
cords from mice sacrificed at 45 dpi was performed on 12 to 15 sections per mouse. Each quadrant from every coronal section of each mouse
was graded for demyelination. Percentage of spinal cord quadrants examined with the pathologic abnormality scores are shown. The number of
mice analyzed in the experiment is listed beside each bar. b Percentage of animals positive for demyelination. Number of animals positive for
demyelination based on morphological analysis are plotted as percentage positive for demyelination in each group. One hundred percent of
mice in the susceptible phenotype showed demyelination in the sections tested, whereas mice with competent immune system did not show
any demyelination
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borderline significance (P = 0.05, rank sum test) for the
increased extent of pathology in the hippocampus and
striatum of Aβ0.β2m0.Hβ2m+.A11+ mice (1.656 ± 0.256,
N = 32) as compared to Aβ0.β2m0.Hβ2m+.B27+ mice
(0.917 ± 0.255, N = 24).
Aβ0.β2m0.Hβ2m+.A11+ and Aβ0.β2m0.Hβ2m+.B27+
transgenic mice show a similar distribution of virus
protein in the brain during the early and late disease
stages
We asked whether failure to control virus antigen
expression in the brain resulted in the slow and di-
minished repair of hippocampus, striatum, and cor-
tex of the Aβ0.β2m0.Hβ2m+.A11+ mice compared to
Aβ0.β2m0.Hβ2m+.B27+ mice (Fig. 3). Animals of the
resistant H-2b haplotype replicate TMEV in brain from 7
to 21 days after intracerebral inoculation. Virus antigen is
expressed abundantly in the hippocampus and cortex but
to a lesser extent in striatum and brain stem. Expression
levels of viral antigens decrease significantly in the brain
by 45 dpi such that only a few antigen-positive cells are
observed. During the early infection of the brain, neurons
are the primary targets of infection. However, a few oligo-
dendrocytes, astrocytes, and macrophages also express
virus antigen.
We quantified the number of virus antigen-positive
cells per ×40 high-power field (h.p.f.) in the cerebellum,
brain stem, cortex, hippocampus, striatum, and corpus callo-
sum of Aβ0.β2m0.Hβ2m+.A11+ and Aβ0.β2m0.Hβ2m+.B27+
mice at 7 (Fig. 5a–f) and 45 dpi (Fig. 5g–l). We chose these
time points because of the similar brain pathology in both
strains at 7 dpi, whereas at 45 dpi brain pathology was sig-
nificantly higher in Aβ0.β2m0.Hβ2m+.A11+ mice compared
to the Aβ0.β2m0.Hβ2m+.B27+ mice. We quantitated
virus antigen-positive cells in areas of maximal pathology
(5 to 11 specimens per experimental group). There were
Fig. 3 Pathology scores of the brain. Pathologic analysis of brain areas (cerebellum, brain stem, cortex, hippocampus, striatum, corpus callosum,
and meninges) at 7 days (a–g) and 45 days (h–n) following TMEV infection (dpi). Mouse strains shown are Aβ0.β2m0.Hβ2m+.A11+ (red open circle)
and Aβ0.β2m0.Hβ2m+.B27+ (blue open square). Pathologic qualitative scores from 0 to 4 are described in the materials and methods. Each symbol
represents one mouse. There were no differences between the two strains in the distribution of brain pathology at 7 days after infection (a–g).
At the 45-day time point, there was less brain pathology in Aβ0.β2m0.Hβ2+.B27+ mice as compared to Aβ0.β2m0.Hβ2m+.A11+mice (P = 0.027, rank
sum test; h–n)
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no significant differences in the number of virus antigen-
positive cells across the brain regions at 7 dpi. Similar
numbers of virus antigen-positive cells were observed
in the all the other regions of the brain of both strains.
Only a few antigen-positive cells were observed in the
cerebellum and brain stem, since these areas demon-
strated minimal pathology.
It was critical to discern whether the minimal repair
observed in Aβ0.β2m0.Hβ2m+.A11+ mice was the result
of virus antigen persistence in brain areas with injury.
Analysis of five Aβ0.β2m0.Hβ2m+.A11+ mice with severe
CNS pathology at 45 dpi showed minimal antigen-positive
cells in the brain areas examined (Fig. 5g–l). The number
of virus antigen-positive cells were not significantly differ-
ent in the majority of areas examined comparing
Aβ0.β2m0.Hβ2m+.A11+ mice to Aβ0.β2m0.Hβ2m+.B27+
mice at 45 dpi. This was the case even though four of five
mice had pathological scores of “4” in striatum and/or
hippocampus (Fig. 3j, k, l). However, more virus
antigen-positive cells were quantified in the cortex of
Aβ0.β2m0.Hβ2m+.A11+ mice (12.2 ± 5.7) compared to
the Aβ0.β2m0.Hβ2m+.B27+ mice (2.7 ± 2.0) and this was
statistically significant (P = 0.04, rank sum test). This
may not be biologically significant as quantification
from just one mouse influenced this result (Fig. 5i). In
addition, Aβ0.β2m0.Hβ2m+.B27+ mice with resolved path-
ology in the striatum and hippocampus also showed min-
imal virus antigen expression in these areas. We concluded
that persistent virus antigen expression in CNS cells
likely did not delay recovery of CNS pathology in
Aβ0.β2m0.Hβ2m+.A11+ mice. Therefore, it is possible
factors other than virus clearance are important in class
I MHC-mediated CNS repair.
Aβ0.β2m0.Hβ2m+.A11+ and Aβ0.β2m0.Hβ2m+.B27+
transgenic mice propagate similar extent of viral RNA in
the brain during TMEV infection
Previous reports indicate that following TMEV infection,
viral RNA persists during chronic stages of the disease,
even though it is often difficult to detect infectious virus
by plaque assay [45]. We developed a sensitive and
quantitative RT-PCR assay to measure the copy number
of TMEV-specific RNA in the brain and spinal cord of
infected mice (Fig. 6a). This assay has shown positive
correlation with virus plaque assay [50]. We evaluated the
level of virus RNA expression in the brain independently
Fig. 4 Pathology of the hippocampus. Paraffin sections stained with hematoxylin and eosin showing the hippocampus following virus infection.
Arrowheads point to the dentate gyrus of the hippocampus that is preserved in all strains. Arrows point to the pyramidal cells of the hippocampus, which
is destroyed in both B27+ and A11+ strains at day 7 DPI but is repaired in B27+ mice by 45 dpi but not repaired in A11+ strains. a Aβ0.β2m0.Hβ2m+.A11+
mouse at 7 dpi. b Aβ0.β2m0.Hβ2m+.B27+ mouse at 7 dpi. c Aβ0.β2m0.Hβ2m+.A11+ mouse at 45 dpi. d Aβ0.β2m0.Hβ2m+.B27+ mouse at 45 dpi.
Note extensive shrinkage of the brain parenchyma in the Aβ0.β2m0.Hβ2m+.A11+ mouse at 45 dpi compared to the Aβ0.β2m0.Hβ2m+.B27+
mouse. Scale bar = 1 mm
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at 7 dpi (Aβ0.β2m0.Hβ2m+.A11+, log10 8.84 ± 0.09;
Aβ0.β2m0.Hβ2m+.B27+, log10 8.84 ± 0.09) and 45 dpi
(Aβ0.β2m0.Hβ2m+.A11+, log10 8.84 ± 0.09; Aβ
0.β2m0.Hβ2m
+.B27+, log10 8.91 ± 0.35). We focused our experiments
primarily to test whether the persistence of severe
brain pathology in Aβ.β2m0.Hβ2m+.A11+ mice was a
consequence of more virus RNA propagation. All ex-
periments were controlled for expression of GAPDH
RNA, which was highly consistent among different
strains. The level of GAPDH-RNA in the brain was
log10 7.40 ± 0.03.
As expected, all mice strains expressed high levels of
virus RNA in the brain during acute infection. Given
the absence of a protective immune response, more
virus RNA copies (log10 12.28 ± 0.06) were detected in
Aβ0.β2m0 mice compared to the other strains. The dif-
ference was statistically significant when virus RNA
copy numbers were compared among all strains for the
brain (P < 0.001, one-way ANOVA). We used the Tukey
test for multiple-pair comparisons of virus copy num-
bers in Aβ0.β2m0 mice relative to virus copy numbers
in the other strains. The viral copy number was not statis-
tically significant when comparing Aβ0.β2m0.Hβ2m+.A11+
mice to Aβ0.β2m0.Hβ2m+.B27+ mice at neither 7 nor 45
dpi (Fig. 6a). This indicates that, in the absence of Aβ
(class II immune response), human class I worked effi-
ciently to limit virus propagation and prevent death and
subsequent injury. Most notable was the comparison of
virus-RNA at the 45 dpi, when Aβ0.β2m0.Hβ2m+.A11+
mice showed severe brain pathology but Aβ0.β2m0.Hβ2m
+.B27+ mice had repaired the injury. There was no differ-
ence in the amount of virus RNA when comparing
Aβ0.β2m0.Hβ2m+.A11+ mice to Aβ0.β2m0.Hβ2m+.B27+
mice at 7 or 45 dpi. Therefore, clearance of virus RNA did
not explain the effect of the human class I MHC on differ-
ential brain repair.
Fig. 5 Virus antigen-positive cells in different brain areas. Brain areas (cerebellum, brain stem, cortex, hippocampus, striatum, and corpus callosum)
at 7 days (a–f) and 45 days (g–l) following TMEV infection (dpi) were quantified for a number of virus antigen-positive cells per ×40 high-power
field (h.p.f) in area of maximal pathology. There were similar numbers of virus antigen-positive cells across the brain regions at both 7 and 45 dpi
(except the cortex at 45 dpi, i)
Wootla et al. Journal of Neuroinflammation  (2016) 13:293 Page 11 of 16
Humoral immune responses are not altered in
Aβ0.β2m0.Hβ2m+.A11+ and Aβ0.β2m0.Hβ2m+.B27+
transgenic mice following TMEV infection
Antibody production is an efficient way to prevent and
control viral infection by the immune system [51]. There-
fore, we asked whether phenotypic differences between
Aβ0.β2m0.Hβ2m+.A11+ mice and Aβ0.β2m0.Hβ2m+.B27+
mice were at least partially based on differences in the
humoral response to the virus. To test this possibility, we
assessed antibody responses in the serum by ELISA di-
rected against purified virus antigens. Serum IgG re-
sponses were measured at 21 (not shown) and 45 dpi
(Fig. 6b). Neither strain of mice developed virus-
specific IgG responses at 21 and 45 dpi. Results from
TMEV-infected strains were identical to IgG levels ob-
served in non-infected littermate controls, which showed
no antivirus antibody responses. In contrast, antibody re-
sponses from immunocompetent mice (SJL/J) showed
strong positive reactivity by ELISA to virus antigen. The
lack of an Aβ gene in these transgenic mice explained the
absence of virus-specific antibody responses because the
class II MHC immune response is necessary for the B cell-
mediated antibody generation. Therefore, a protective
antibody response does not account for phenotypic
differences seen between Aβ0.β2m0.Hβ2m+.A11+ and
Aβ0.β2m0.Hβ2m+.B27+ mice with respect to their re-
generative ability in hippocampus and striatum.
Discussion
To our best knowledge, this is the first study to demon-
strate human class I MHC gene-mediated survival and
modulation of viral infectivity in a transgenic mouse
model devoid of a class II immune response. Transgenic
expression of either A11 or B27 prevented the pheno-
typic consequence of persistent viral infection; in this
case, chronic demyelination. Of interest, the extent of
pathology observed in Aβ0.β2m0.Hβ2m+.A11+ or
Aβ0.β2m0.Hβ2m+.B27+ mice was less than that observed
in Aβ0 mice with endogenous mouse class I H-2b alleles.
This unexpected finding suggests that the human A11 or
B27 gene in this scenario functions even more efficiently
than the endogenous murine class I H-2b alleles in limit-
ing early pathologic damage. This occurred despite an
otherwise murine-immune repertoire with mouse T cells
and mouse T cell receptors. These findings support the
hypothesis that human class I molecules are critical for
controlling the extent of pathologic damage following
intracerebral virus infection.
Previous studies demonstrate that class I-deficient
(β2m0) [52–54] or class II-deficient (Aβ0) [47, 55] mice
survive encephalitic phase, but, over time, develop spinal
cord demyelination. These results were confirmed in the
present study. The results from the β2m0 or Aβ0 mice
indicate that neither independent CD4+ nor CD8+ T
cells are required for early limitation of virus replication
in the brain, since these mice survive the acute infection.
However, both strains of mice fail to clear the virus com-
pletely, and therefore, persistent infection remains in the
spinal cord. In addition, the results from the β2m0 or
Aβ0 mice indicate that either class I-restricted or class
II-restricted T cells are required independently for subse-
quent demyelination. The use of CD4 and CD8 knockout
mice confirms this finding [56]. This is in contrast to the
infection of double deficient Aβ0.β2m0 mice, which fail to
Fig. 6 a Virus RNA expression. Levels of virus RNA expression in mice at 7, 21, and 45 dpi analyzed in the brain. Levels of viral capsid VP2 RNA
message were quantified by light cycler PCR. There were no significant differences between the two strains in the levels of virus RNA expression
at 7, 21, and 45 dpi. The levels of expression of GAPDH RNA were consistent among the groups (brains log10 7.40 ± 0.03). b Virus-specific humoral
immune responses. ELISA for serum IgG antibodies at 45 days after infection directed against purified TMEV antigens in Aβ0.β2m0.Hβ2m+.A11+and
Aβ0.β2m0.Hβ2m+.B27+ mice. Uninfected C57BL/6 mice were used as a negative control. As a positive control, immunocompetent SJL/J mice were used.
Five animals were tested in each experimental group
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clear the acute virus encephalitis and die possibly before
demyelination occurs in the spinal cord [48]. In the
present experiment, the disease in Aβ0.β2m0.Hβ2m+.A11+
and Aβ0.β2m0.Hβ2m+.B27+ mice was similar to the estab-
lished model. These mice had substitution of mouse class
I alleles with human A11 or B27 genes, and thus, they sur-
vived acute encephalitis similarly to Aβ0 mice. In addition,
these transgenic mice were similar to Aβ0 mice [57] re-
garding the virus-specific antibody responses, because
none of the A11+, B27+ or the Aβ0 mice developed
antibody responses.
We considered two hypotheses to explain the differences
in brain pathology and repair as a result of human class I
expression following chronic infection. One possibility was
that a particular class I immune response influenced more
injury to brain neurons. In this scenario, the presence of
A11+ transgene would actively contribute to injury,
whereas the reparative response in Aβ0.β2m0.Hβ2m+.B27+
transgenic mice was passive, and thus occurred independ-
ently of the MHC haplotype. The other possibility was that
the reparative response in the Aβ0.β2m0.Hβ2m+.B27+ trans-
genic mice was active, such that a protective response was
necessary for neuronal repair dependent of human class I
MHC. To address these two possibilities, we tested the
reparative response in Aβ0.β2m0.Hβ2m+ mice, which
expressed only Hβ2m but no specific class I MHC allele.
Of importance, these mice showed CNS repair follow-
ing virus infection. The brain pathologic score for
Aβ0.β2m0.Hβ2m+ mice at 45 days after infection was
0.429 ± 0.104 (N = 77). There was a statistical trend (P =
0.070, rank sum test) for less brain pathology in
Aβ0.β2m0.Hβ2m+ mice as compared to Aβ0.β2m0.Hβ2m
+.A11+ mice (0.964 ± 0.137, N = 112). There was no statis-
tical difference (P = 0.641, rank sum test) between the
brain pathology in Aβ0.β2m0.Hβ2m+ mice as compared to
Aβ0.β2m0.Hβ2m+.B27+ mice (0.403 ± 0.198, N = 77). This
supports the hypothesis that brain repair was an active
process since mice with only Hβ2m+ showed some repair.
The second hypothesis was that the class I MHC or pos-
sibly even Hβ2m alone may have provided a signal that
promoted repair. However, since the differences for brain
pathology comparing Aβ0.β2m0.Hβ2m+ mice did not
reach statistical significance, we consider this less likely.
However, the most striking aspect of these studies
was the difference in how human MHC class I genes
influenced repair or persistent brain damage after the
initial injury. Infection of Aβ0.β2m0.Hβ2m+.A11+ and
Aβ0.β2m0.Hβ2m+.B27+ mice resulted in a similar extent
of damage in the hippocampus, striatum, and cortex at
7 dpi. In particular, there was striking loss of pyramidal
cells of the hippocampus with evident necrosis and loss of
architecture. However, at 45 dpi, Aβ0.β2m0.Hβ2m+.B27+
mice showed remarkable repair of these structures,
whereas Aβ0.β2m0.Hβ2m+.A11+ mice featured persistent
injury. A very likely explanation for these findings is the
control of virus antigen expression or virus RNA in the
Aβ0.β2m0.Hβ2m+.B27+ mice but persistent virus infection
in Aβ0.β2m0.Hβ2m+.A11+ mice. Surprisingly, we found
that both strains of mice control virus infection such that
minimal virus antigen-positive cells were quantified in the
brain at 45 dpi. In addition, virus RNA transcripts were
not different in the brain in these two strains. There was
also a lack of demyelination in the spinal cord during
chronic infection. Thus, the differential effect on repair
cannot be explained by failure of MHC class I presenta-
tion in the A11+ strain resulting in virus persistent in-
jury. In contrast, the data support the hypothesis that
repair occurs independently of viral persistence and is
an inherent property of the interaction between the
nervous system and the class I MHC. One important
limitation is that only one transgenic line from each of
the Aβ0.β2m0.Hβ2m+.A11+ and Aβ0.β2m0.Hβ2m+.B27+
mice were used to derive our data. We cannot exclude the
possibility that there is another gene, closely linked to the
MHC genes, used to make these mice as the reason for
the brain repair observed in the Aβ0.β2m0.Hβ2m+.B27+
mice. We await confirmation of these results by other
investigators.
What are the potential mechanisms by which the
MHC I class arm of the immune response contributes to
brain repair? Previous conventional wisdom taught that
immune factors are detrimental to the CNS. However,
recent data indicate a critical role in CNS repair for cer-
tain aspects of the innate [58] and adaptive immune re-
sponses [59]. Increasing evidence implies that T cells are
necessary for CNS repair. Studies from our laboratory
using immune RAG-1-deficient mice point to failure of
remyelination following toxin-induced demyelination
[60]. Mice lacking or depleted of CD4+ or CD8+ T cells
also exhibit reduced remyelination. Others have demon-
strated that immune-activated T cells and macrophages
are beneficial in spinal cord injury [61]. Immune cells
actively secrete trophic factors to promote CNS repair
[62]. These factors, including interferon gamma [63],
interleukin 6 [41, 64], and TNF [65, 66], are secreted by
T cells and macrophages and promote neuronal differen-
tiation and neurite outgrowth. Many of these factors
promote neuronal survival, neuronal stem cell prolifera-
tion, neurite elongation, or prevent cell death in vitro.
Differential MHC class I expression in our transgenic
mice may have altered neural stem cell or progenitor re-
cruitment. For example, there is evidence that neural
stem cells express co-stimulatory molecules (i.e., CD80
and CD87) differentially regulated by the inflammatory
response [67]. Furthermore, implantation of immune-
activated dendritic cells in the injured adult spinal cord
may activate endogenous neural stem cells leading to de
novo neurogenesis [68, 69]. Understanding how differential
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expression of human class I MHC mediates repair is be-
yond the scope of this paper and will require extensive
investigation.
Conclusions
Based on the results from this study, we propose the fol-
lowing model to explain the effect of differential class I
MHC alleles on CNS injury or repair. In the absence of
an immune response (i.e., Aβ0.β2m0 mice), animals die
of overwhelming encephalitis as a result of widespread
infection. The presence of either class II (i.e., Aβ0 mice)
or class I (i.e., β2m0 mice) immune response is sufficient
to overcome the fatal encephalitis. These mice clear
the virus from neurons in the brain but develop virus
persistence in glial cells and macrophages leading to
chronic spinal cord demyelination. In the presence of
both a competent class I and class II response (i.e.,
C57Bl/6 – H2b mice), virus is cleared without subsequent
demyelination or virus persistence. Differential class I al-
leles appear to play a critical role in determining whether
the final outcome of injury is persistent neuronal dropout
(i.e., Aβ0.β2m0.Hβ2m+.A11+ mice) or neural repair (i.e.,
Aβ0.β2m0.Hβ2m+.B27+ mice).
Additional file
Additional file 1: Figure S1. Spinal cord lesions in mice infected for
45 days with DA strain of TMEV. The class I antigen expression was
up-regulated in areas of injury. Panel A. Immunoperoxidase A11 staining in
Aβ0.β2m0.Hβ2m+.A11+ mice. Panel B. B27 staining in Aβ0.β2m0.Hβ2m+.A11+
mice. Panel C. B27 staining in Aβ0.β2m0.Hβ2m+.B27+ mice. Panel D. A11
staining in Aβ0.β2m0.Hβ2m+.B27+ mice. Images were collected at ×60. The
weak staining is either the result of the quality of antibodies that do not
work well with immunocytochemistry or the fact that the CNS normally has
low level expression of MHC. Scale bar = 20 μm. (TIF 1561 kb)
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